Filed for bankruptcy in Oct 2024
SIOX - Sio Gene Therapies Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
SIOX price evolution
SIOX
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.35 | $0.35 | $1.61 | $1.73 |
| Inventory | ||||
| Total current assets | $53.74 | $59.13 | $71.74 | $90.07 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $3.35 | $3.34 | $3.24 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $53.75 | $62.48 | $75.08 | $93.31 |
| Current liabilities | ||||
| Accounts payable | $1.96 | $2.24 | $3.98 | $6.61 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.83 | $9.15 | $13 | $15.14 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.83 | $10.7 | $14.73 | $17.04 |
| Shareholders' equity | ||||
| Retained earnings | -$874.44 | -$871.36 | -$862.96 | -$849.63 |
| Other shareholder equity | $0.33 | $0.33 | $0.34 | $0.34 |
| Total shareholder equity | ||||
| (in millions $) | 1 May 2022 | 30 Apr 2021 | 30 Apr 2020 | 30 Apr 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $118.99 | $80.75 | $107 | |
| Short term investments | ||||
| Net receivables | $1.61 | $6 | $1.71 | $1.73 |
| Inventory | ||||
| Total current assets | $71.74 | $132.33 | $85.43 | $114.58 |
| Long term investments | ||||
| Property, plant & equipment | $3.34 | $0.48 | $0.8 | $1.28 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.81 | $8.25 | $8.12 | |
| Total investments | ||||
| Total assets | $75.08 | $135.15 | $93.68 | $122.71 |
| Current liabilities | ||||
| Accounts payable | $3.98 | $1.34 | $4.41 | $1.7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13 | $10.85 | $32.04 | $43.5 |
| Long term debt | $22.99 | |||
| Total noncurrent liabilities | $0.93 | $0.08 | $22.99 | |
| Total debt | ||||
| Total liabilities | $14.73 | $11.78 | $32.12 | $66.49 |
| Shareholders' equity | ||||
| Retained earnings | -$862.96 | -$791.07 | -$758.64 | -$686.02 |
| Other shareholder equity | $0.34 | $0.34 | -$0.06 | $0.91 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $8.53 | $13.08 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0 | $0.29 | ||
| Interest expense | -$0.01 | |||
| Net income | ||||
| Net income | -$8.41 | -$13.32 | ||
| Income (for common shares) | ||||
| (in millions $) | 1 May 2022 | 30 Apr 2021 | 30 Apr 2020 | 30 Apr 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $71.56 | $42.2 | $69.17 | $127.02 |
| Operating income | -$42.2 | -$69.17 | -$127.02 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.26 | -$0.21 | $0.44 | $0.13 |
| Interest expense | -$0.03 | $0.8 | $4.38 | $7.53 |
| Net income | ||||
| Net income | -$71.89 | -$32.42 | -$72.63 | -$129.06 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.1 | -$0.28 | $3.65 | $4.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.44 | $1.44 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.86 | -$8.96 | -$55.26 | -$37.07 |
| (in millions $) | 1 May 2022 | 30 Apr 2021 | 30 Apr 2020 | 30 Apr 2019 |
|---|---|---|---|---|
| Net income | -$32.42 | -$72.63 | -$129.06 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$46.59 | -$67.47 | -$134.21 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $3.65 | $12.39 | -$0.26 | -$0.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.44 | $73.62 | $41.48 | $87.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$55.26 | $39.42 | -$26.25 | -$47.34 |
News
Fundamentals
| Market cap | $30.70M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 73.98M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 11.12 |
| Quick ratio | N/A |